Inactive Instrument

Highlights Suda Ltd Australian S.E.

Equities

EMS

AU000000EMS2

End-of-day quote Australian S.E. Other stock markets
- ^AUD	-

06-13	Arovella Therapeutics, Teva Pharmaceuticals End ZolpiMist License Agreement	MT
06-05	Arovella Therapeutics Completes Process Development for ALA-101 Manufacturing; Shares Jump 9%	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Arovella Therapeutics, Teva Pharmaceuticals End ZolpiMist License Agreement	06-13	MT
Arovella Therapeutics Completes Process Development for ALA-101 Manufacturing; Shares Jump 9%	06-05	MT
Arovella Therapeutics Receives Firm Commitments for About AU$12.5 Million Raise	03-26	MT
Arovella Therapeutics' ALA-101-onCARlytics Collaboration with Imugene Ends; Shares Down 12%	03-20	MT
Arovella Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-28	CI
Arovella Therapeutics Secures AU$2 Million Tax Rebate for Fiscal Year 2023	11-20	MT
Arovella Therapeutics Secures License for Tumor Targeting Antibody; Shares Fall 6%	12/10/23	MT
Arovella Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	31/08/23	CI
Arovella Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2022	22/02/23	CI
Arovella Therapeutics Limited and Imugene Announces Collaboration Advances to Next Phase of Testing	09/02/23	CI
Arovella Therapeutics Secures Exclusive Option to License Cytokine Technology for Cancer Therapy Platform	20/12/22	MT
Arovella Therapeutics Ltd Options Cytokine Technology to Enhance iNKT platform	19/12/22	CI
Arovella Therapeutics Receives R&D Tax Rebate	29/11/22	MT
Arovella Therapeutics Limited Announces Europe Patent to Be Granted for Inkt Cell Therapy Platform	06/11/22	CI
Arovella Therapeutics Ltd Collaborates with Imugene Limited Using its OnCARlytics Platform	26/09/22	CI
Arovella Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2022	31/08/22	CI
Arovella Therapeutics Limited Provides Sumatriptan Update	28/06/22	CI
Arovella Therapeutics Partner STADA Begins Commercial Launch of Insomnia Drug in Australia	22/06/22	MT
Arovella Therapeutics Limited Announces ZolpiMist Launch Australia	22/06/22	CI
Arovella Therapeutics Adopts WEF Framework for ESG Reporting	09/06/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Suda Ltd Australian S.E.

Equities

EMS

AU000000EMS2

Highlights

Filters